CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: * find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely * measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood * determine if CNF2024 as a single agent or in combination with trastuzumab can stop breast cancer cells from growing

Key facts

Study ID

NCT00412412

Run by

Biogen

People needed

34

Starts

2007-12-01

Expected to finish

2011-04-01

Last updated by the study team

2012-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Tampa, Florida, United States
• Research Site — New York, New York, United States
• Research site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.